Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib

被引：0
|
作者：
Fan Wu
Gopal Krishna
Sekhar Surapaneni
机构：
[1] Bristol Myers Squibb,Nonclinical Research and Development
[2] Bristol Myers Squibb,Clinical Pharmacology
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Drug–drug interaction; PBPK; Metabolic inhibition; Simcyp; Fedratinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 473
页数：12
相关论文
共 50 条
  • [31] Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential
    Willmann, Stefan
    Coboeken, Katrin
    Kapsa, Stefanie
    Thelen, Kirstin
    Mundhenke, Markus
    Fischer, Kerstin
    Huegl, Burkhard
    Mueck, Wolfgang
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (05): : 656 - 665
  • [32] Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling
    Dong, Jin
    Garcia, Luna Prieto
    Huang, Yingbo
    Tang, Weifeng
    Lundahl, Anna
    Elebring, Marie
    Ahlstrom, Christine
    Vildhede, Anna
    Sjogren, Erik
    Nagard, Mats
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (04) : 825 - 835
  • [33] The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling
    Kato, Motohiro
    Shitara, Yoshihisa
    Sato, Hitoshi
    Yoshisue, Kunihiro
    Hirano, Masaru
    Ikeda, Toshihiko
    Sugiyama, Yuichi
    PHARMACEUTICAL RESEARCH, 2008, 25 (08) : 1891 - 1901
  • [34] Physiologically Based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb-Drug Interaction
    Brantley, S. J.
    Gufford, B. T.
    Dua, R.
    Fediuk, D. J.
    Graf, T. N.
    Scarlett, Y. V.
    Frederick, K. S.
    Fisher, M. B.
    Oberlies, N. H.
    Paine, M. F.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (03):
  • [35] Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole
    Maxime Le Merdy
    Ming-Liang Tan
    Dajun Sun
    Zhanglin Ni
    Sue-Chih Lee
    Andrew Babiskin
    Liang Zhao
    European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 41 - 51
  • [36] Physiologically Based Pharmacokinetic Modeling Characterizes the Drug-Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment
    Wu, Wanhong
    Lin, Rongfang
    Ke, Meng
    Ye, Lingling
    Lin, Cuihong
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (07): : 848 - 858
  • [37] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE DRUG-DRUG INTERACTION (DDI) RISK OF ALECTINIB.
    Cleary, Y.
    Gertz, M.
    Morcos, P. N.
    Youdim, K.
    Fowler, S.
    Yu, L.
    Sekiguchi, N.
    Takanashi, K.
    Kaneko, A.
    Phipps, A.
    Parrott, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S40 - S40
  • [38] Physiologically-based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients
    Amiel, Magali
    Ke, Alice
    Gelone, Steven P.
    Jones, Hannah M.
    Wicha, Wolfgang
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 589 - 598
  • [39] Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
    Liu, Hongrui
    Yu, Yiqun
    Guo, Nan
    Wang, Xiaojuan
    Han, Bing
    Xiang, Xiaoqiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [40] Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
    Ruijuan Xu
    Weihong Ge
    Qing Jiang
    European Journal of Clinical Pharmacology, 2018, 74 : 755 - 765
12345